Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
4.6
Journals
Pharmaceuticals
Special Issues
Medical Cannabis and Its Derivatives
share announcement

Medical Cannabis and Its Derivatives

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Natural Products".

Deadline for manuscript submissions: 25 May 2024 | Viewed by 1906

Special Issue Editors

Dr. Priscila Mazzola

E-Mail Website
Guest Editor
Faculty of Pharmaceutical Sciences, University of Campinas (UNICAMP), Campinas 13083-871, Brazil
Interests: drug delivery; natural products; photoprotection; product development; topical delivery; transdermal products
Prof. Dr. José Luiz Costa

E-Mail Website
Guest Editor
Faculty of Pharmaceutical Sciences, University of Campinas (UNICAMP), Campinas 13083-871, Brazil
Interests: toxicology; analytical toxicology; forensic and clinical toxicology; mass spectrometry; chromatography

Special Issue Information

Dear Colleagues,

This Special Issue aims to provide a comprehensive overview of the latest research developments in the field of medical cannabis and its derivatives. It will explore the various medical applications of cannabis and its compounds, including CBD, THC, and other cannabinoids. It will also examine the potential risks and benefits associated with medical cannabis use, as well as the legal and regulatory challenges surrounding its use.

Topics:

The Special Issue will comprise original research articles, reviews, and case reports covering a range of topics related to medical cannabis and its derivatives, including, but not limited to, the following:

  • The pre-clinical and clinical pharmacology and therapeutic potential of cannabinoids in different medical conditions;
  • The role of the endocannabinoid system in health and disease and how cannabis-derived compounds can interact with this system;
  • The development and testing of cannabis-based pharmaceuticals, including clinical trials and regulatory issues;
  • The use of medical cannabis in specific population groups, such as pediatric patients, including the potential risks and benefits;
  • Delivery systems of cannabis extracts and/or their components, including studies employing traditional and modern alternatives.

Dr. Priscila Mazzola
Prof. Dr. José Luiz Costa
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • medicinal cannabis
  • cannabidiol
  • tetrahydrocannabinol
  • dosing
  • drug delivery

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 2403 KiB  
Article
Evaluating Sex Differences in Efficacy, Safety and Pharmacokinetics in Patients Treated with Cannabis by a Metered-Dose Inhaler
by Joshua Aviram, Marek Glezerman, Eytan Hayam, Rostislav Belobrov, Shiri Procaccia, David Meiri and Elon Eisenberg
Pharmaceuticals 2023, 16(10), 1426; https://0-doi-org.brum.beds.ac.uk/10.3390/ph16101426 - 08 Oct 2023
Viewed by 1183
Abstract
Background: Clinical studies on medical cannabis (MC) treatment have shown sex-related differences, including higher susceptibility to adverse events among women and greater analgesia among men. Here, we used the Syqe metered-dose inhaler (MDI) and a single chemovar to analyze sex differences. Methods: A [...] Read more.
Background: Clinical studies on medical cannabis (MC) treatment have shown sex-related differences, including higher susceptibility to adverse events among women and greater analgesia among men. Here, we used the Syqe metered-dose inhaler (MDI) and a single chemovar to analyze sex differences. Methods: A total of 1249 Israeli chronic pain patients were assessed for pain intensity, sleep and adverse events (AEs) over 240 days. Results: Following the first two weeks, no significant sex differences were found in the effectiveness or safety of MC treatment (p > 0.05). Inhaled Δ9-THC doses did not vary significantly between sexes (p > 0.05) except in the first month of treatment. Pain reduction and sleep improvement were similar for both sexes (p > 0.05). The overall rate of AEs was equal and relatively low at 10% (n = 65, 10% of women and n = 60, 10% of men; χ2 (1) = 0.05, p = 0.820). A secondary analysis of pharmacokinetic data showed no significant differences between sexes in Δ9-THC and its metabolite pharmacokinetics, cardiovascular measures, or AE severity (p > 0.05). Conclusions: Uniform MC treatment via the Syqe MDI showed no sex differences in short-term effectiveness, safety and pharmacokinetics, nor in long-term effects, under “real-life” conditions. These findings provide insights into MC treatment which may inform clinical practice and policy-making in the field. Full article
(This article belongs to the Special Issue Medical Cannabis and Its Derivatives)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop